Information Provided By: 
Fly News Breaks for August 21, 2019
SRPT
Aug 21, 2019 | 08:13 EDT
Needham analyst Chad Messer lowered his price target on Sarepta to $170, saying the FDA's Complete Response Letter on golodirsen ahead of its August 19th PDUFA date was a surprising setback and will likely result in delay to market. The analyst still keeps his Buy rating on Sarepta and notes that its casimersen new drug application submission remains on track. Messer adds that gene therapy is expected to become an increasing contributor to Sarepta value, in spite of the recent delay in timelines.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
